Indivior Pharmaceuticals earnings were $210.0M for the trailing 12 months ending Dec 31, 2025, with 3,260% growth year over year. The latest INDV earnings report on Dec 31, 2025 announced Q4 2025 earnings of $102.0M, up 142.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, INDV reported annual earnings of $210.0M, with 2,900% growth. The next INDV earnings date is Apr 23, 2026.
INDV past earnings growth
How has INDV's earnings growth performed historically?
Indivior Pharmaceuticals Earnings Reports & History FAQ
What were Indivior Pharmaceuticals's earnings last quarter?
On INDV's earnings call on Invalid Date, Indivior Pharmaceuticals (NASDAQ: INDV) reported Q4 2025 earnings per share (EPS) of $0.81, up 406.25% year over year. Total INDV earnings for the quarter were $102.00 million. In the same quarter last year, Indivior Pharmaceuticals's earnings per share (EPS) was $0.16.
When does Indivior Pharmaceuticals report earnings?
The next INDV earnings call is Invalid Date. Add INDV to your watchlist to be reminded of Indivior Pharmaceuticals's next earnings date.
Is Indivior Pharmaceuticals profitable or losing money?
As of the last Indivior Pharmaceuticals earnings report, Indivior Pharmaceuticals is currently profitable. Indivior Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $210.00 million, a 2,900% increase year over year.
What was INDV's earnings growth in the past year?
As of Indivior Pharmaceuticals's earnings date in Invalid Date, Indivior Pharmaceuticals's earnings has grown 3,260% year over year. This is 3,205.41 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 54.59%. INDV earnings in the past year totalled $210.00 million.
What are Indivior Pharmaceuticals's earnings expectations?
The current EPS estimate for Indivior Pharmaceuticals's earnings report in Invalid Date is $0.66.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.